

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ZELIRA THERAPEUTICS LIMITED
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jason Peterson
Date of last notice	11 June 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	i. Celtic Capital Pty Ltd <The Celtic Capital A/C> (Director/Shareholder) ii. Celtic Capital Pte Ltd <Investment 1 A/C> (Director/Shareholder) iii. Professional Payment Services Pty Ltd (Director/Shareholder) iv. Wicklow Capital Pty Ltd <Tipperary A/C> (Director/Shareholder) v. Sunset Capital Management Pty Ltd <Sunset Superfund> (Director/Shareholder) vi. Celtic Capital Pty Ltd <Income A/C> (Director/Shareholder) vii. CPS Capital No 3 Pty Ltd (Director/Shareholder)
Date of change	23 December 2019
No. of securities held prior to change	i. 11,200,000 ordinary shares ii. 5,800,000 ordinary shares iii. 538,230 ordinary shares iv. 1,642,105 ordinary shares v. 55,413,630 ordinary shares v. 8,000,000 options (\$0.03125; 17/11/2021)

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Class	A. Class A performance rights B. Class B performance rights
Number acquired	vi. 4,375,000 Class A performance rights vi. 4,375,000 Class B performance rights vii. 1,875,000 Class A performance rights vii. 1,875,000 Class B performance rights
Number disposed	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	A. \$0.0001 as approved by shareholders at the 2019 Annual General Meeting. The terms and conditions of the Performance Rights are details in Schedule 4 and 6 of the Notice of Annual General Meeting dated 25 October 2019. B. \$0.0001 as approved by shareholders at the 2019 Annual General Meeting. The terms and conditions of the Performance Rights are details in Schedule 5 and 6 of the Notice of Annual General Meeting dated 25 October 2019.
No. of securities held after change	i. 11,200,000 ordinary shares ii. 5,800,000 ordinary shares iii. 538,230 ordinary shares iv. 1,642,105 ordinary shares v. 55,413,630 ordinary shares v. 8,000,000 options (\$0.03125; 17/11/2021) vi. 4,375,000 Class A performance rights vi. 4,375,000 Class B performance rights vii. 1,875,000 Class A performance rights vii. 1,875,000 Class B performance rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	A. As approved by shareholders on 28 November 2019 B. As approved by shareholders on 28 November 2019

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ZELIRA THERAPEUTICS LIMITED
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Harry Karelis
Date of last notice	17 November 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Gemelli Nominees Pty Ltd <Gemelli Family A/C> - Director/shareholder
Date of change	23 December 2019
No. of securities held prior to change	49,587,680 ordinary shares 6,000,000 options (\$0.03125; 17/11/2021)
Class	A. Class A performance rights B. Class B performance rights
Number acquired	A. 6,250,000 B. 6,250,000
Number disposed	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	A. \$0.0001 as approved by shareholders at the 2019 Annual General Meeting. The terms and conditions of the Performance Rights are details in Schedule 4 and 6 of the Notice of Annual General Meeting dated 25 October 2019. B. \$0.0001 as approved by shareholders at the 2019 Annual General Meeting. The terms and conditions of the Performance Rights are details in Schedule 5 and 6 of the Notice of Annual General Meeting dated 25 October 2019.
No. of securities held after change	49,587,680 ordinary shares 6,000,000 options (\$0.03125; 17/11/2021) 6,250,000 Class A performance rights 6,250,000 Class B performance rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	A. As approved by shareholders on 28 November 2019 B. As approved by shareholders on 28 November 2019

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ZELIRA THERAPEUTICS LIMITED
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Richard Hopkins
Date of last notice	16 July 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	i. Vanhop Pty Ltd <Vanhop Super Fund A/C> - Director and beneficiary ii. Mr Richard Miles Hopkins & Ms Maya Maureen vanden Dreisen <Jesam A/C> - Beneficiary
Date of change	A. 23 December 2019 B. 23 December 2019 C – G. 19 February 2019
No. of securities held prior to change	i. 700,000 ordinary shares ii Nil

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	<ul style="list-style-type: none"> A. Class A performance rights B. Class B performance rights C. Unlisted options with an exercise price of \$0.10 each, vesting immediately and expire on 19 February 2022 D. Unlisted options with an exercise price of \$0.15 each, subject to vesting conditions vesting on 16 October 2019 and expire on 19 February 2022 E. Unlisted options with an exercise price of \$0.20 each, subject to vesting conditions vesting on 16 October 2019 and expire on 19 February 2022 F. Unlisted options with an exercise price of \$0.28 each, vesting on 16 October 2020 and expire on 19 February 2022 G. Unlisted options with an exercise price of \$0.30 each, vesting on 16 October 2020 and expire on 19 February 2022
Number acquired	<ul style="list-style-type: none"> i. 3,125,000 Class A performance rights i. 3,125,000 Class B performance rights ii 3,125,000 Class A performance rights ii 3,125,000 Class B performance rights ii 25,000,000 Unlisted options
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	<ul style="list-style-type: none"> A. \$0.0001 as approved by shareholders at the 2019 Annual General Meeting. The terms and conditions of the Performance Rights are details in Schedule 4 and 6 of the Notice of Annual General Meeting dated 25 October 2019. B. \$0.0001 as approved by shareholders at the 2019 Annual General Meeting. The terms and conditions of the Performance Rights are details in Schedule 5 and 6 of the Notice of Annual General Meeting dated 25 October 2019. C – G. Nil consideration - issued as part director services – refer to the Notice of the General Meeting held on 18 February 2019 for further details

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<ul style="list-style-type: none"> i. 700,000 ordinary shares i. 3,125,000 Class A performance rights i. 3,125,000 Class B performance rights ii. 3,125,000 Class A performance rights ii. 3,125,000 Class B performance rights ii. 5,000,000 unlisted options with an exercise price of \$0.10 each, vesting immediately and expire on 19 February 2022 ii. 5,000,000 unlisted options with an exercise price of \$0.15 each, subject to vesting conditions vesting on 16 October 2019 and expire on 19 February 2022 ii. 5,000,000 unlisted options with an exercise price of \$0.20 each, subject to vesting conditions vesting on 16 October 2019 and expire on 19 February 2022 ii. 5,000,000 unlisted options with an exercise price of \$0.28 each, vesting on 16 October 2020 and expire on 19 February 2022 ii. 5,000,000 unlisted options with an exercise price of \$0.30 each, vesting on 16 October 2020 and expire on 19 February 2022
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	A. As approved by shareholders on 28 November 2019 B. As approved by shareholders on 28 November 2019 C – G. 1 As approved by shareholders on 18 February 2019

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.